Dopamine-related genes and their relationships to monoamine metabolites in CSF

Biological Psychiatry

Volumn 40, Issue 10, 1996, Pages 1032-1043

  Jönsson, Erik ^a,c   Sedvall, Göran ^a   Brené, Stefan ^a   Gustavsson, J Petter ^a   Geijer, Thomas ^a   Terenius, Lars ^a   Crocq, Marc Antoine ^b   Lannfelt, Lars ^c   Tylec, Alexandra ^a   Sokoloff, Pierre ^d   Schwartz, Jean Charles ^d   Wiesel, Frits Axel ^e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Centre Hospitalier de Rouffach   (France)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d CENTRE PAUL BROCA   (France)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

cerebrospinal fluid; dopamine receptor genes; monoamine metabolites; tyrosine hydroxylase gene

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE RECEPTOR; HOMOVANILLIC ACID; MONOAMINE; TYROSINE 3 MONOOXYGENASE;

ADULT; ARTICLE; BRAIN; CEREBROSPINAL FLUID; FEMALE; GENETICS; GENOTYPE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0030589013     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-3223(95)00581-1     Document Type: Article

References (80)

1. Ågren H (1981): Biological markers in major depressive disorder: a clinical and multivariate study. Thesis. Uppsala University, Uppsala.
2. Åsberg M, Bertilsson L, Thorén P, Träskman L (1978): CSF monoamine metabolites in depressive illness. In Garattini S (eds), Depressive Disorders. Stuttgart: Schattauer, pp 293-305.
3. Åsberg M, Bertilsson L, Rydin E, Schalling D, Thorén P, Träskman-Bendz L (1981): Monoamine metabolites in cerebrospinal fluid in relation to depressive illness, suicidal behavior and personality. In Angrist B, Burrows GD, Lader M, Lingjaerde O, Sedvall G, Wheatley D (eds), Recent Advances in Neuropsycho-Pharmacology. Oxford and New York: Pergamon Press, pp 257-271.
4. Åsberg M, Nordström P, Träskman-Bendz L (1986): Cerebrospinal fluid studies in suicide. An overview. Ann N Y Acad Sci 487:243-255.
5. Bertilsson L, Åsberg M (1984): Amine metabolites in the cerebrospinal fluid as a measure of central neurotransmitter function: Methodological aspects. In Usdin E, Åsberg M, Bertilsson L, Sjöqvist F (eds), Frontiers in Biochemical and Pharmacological Research in Depression. New York: Raven Press, pp 27-34.
6. Bertilsson L, Åsberg M, Thorén P (1974): Differential effect of chlorimipramine and nortriptyline on cerebrospinal fluid metabolites of serotonin and noradrenaline in depression. Eur J Clin Pharmacol 7:365-368.
7. Bjerkenstedt L, Edman G, Hagenfeldt L, Sedvall G, Wiesel F-A (1985): Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry 147:276-282.
8. Blennow K, Wallin A, Gottfries CG, et al (1993a): Cerebrospinal fluid monoamine metabolites in 114 healthy individuals. Eur Neuropsychopharmacol 3:55-61.
9. Blennow K, Wallin A, Gottfries CG, Månsson J-E, Svennerholm L (1993b): Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid. J Neural Transm Park Dis Dement Sect 5:5-15.
10. Bowers MB, Heninger GR, Gerbode F (1969): Cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in psychiatric patients. Int J Neuropharmacol 8:225-262.
11. Brewerton TD, Berettini WH, Nurnberger JI Jr, Linnoila M (1988): Analysis of seasonal fluctuations of CSF monoamine metabolites and neuropeptides in normal controls: Findings with 5HIAA and HVA. Psychiatry Res 23:257-265.
12. Brown GL, Linnoila MI (1990): CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence. J Clin Psychiatry 51:31-41.
13. Cohen J, Cohen P (1983): Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences, 2nd ed. Hillsdale, NJ: Lawrence Erlbaum.
14. Crocq M-A, Mant R, Asherson P, et al (1992): Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. J Med Genet 29:858-860.
15. Crocq MA, Duval F, Mayerova A, Sokoloff P, Mokrani MC, Macher JP (1995): Clinical and functional correlates of a dopamine D3 receptor polymorphism. Hum Psychopharmacol 10:19-24.
16. Csernansky JG, Faull KF, Pfefferbaum A (1988): Seasonal changes of CSF monoamine metabolites in psychiatric patients: What is the source? Psychiatry Res 25:361-363.
17. Di Bella D, Catalano M, Strukel A, Nobile M, Novelli E, Smeraldi E (1994): Distribution of the MscI polymorphism of the dopamine D3 receptor in an Italian psychotic population. Psychiatr Genet 4:39-42.
18. Eklundh T, Fernström V, Nordin C (1994): Influence of tapping time and atmospheric pressure on concentrations of monoamine metabolites in the cerebrospinal fluid: A prospective study in female volunteers. J Psychiatr Res 28:511-517.
19. Faustman WO, Elliot PJ, Ringo DL, Faull KF (1993): CSF 5-HIAA and atmospheric pressure: Failure to replicate. Biol Psychiatry 33:61-62.
20. Gateless D, Stanley M, Träskman-Bendz L, Gilroy J (1974): The influence of the lying and sitting positions on the gradients of 5-HIAA and HVA in lumbar cerebrospinal fluid. Biol Psychiatry 19:1585-1589.
21. Geijer T, Neiman J, Rydberg U, et al (1994): Dopamine D2 receptor gene polymorphisms in Scandinavian chronic alcoholics. Eur Arch Psychiatry Clin Neurosci 244:26-32.
22. Gejman PV, Ram A, Gelernter J, et al (1994): No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient gel electrophoresis. JAMA 271:204-208.
23. Gjerris A, Werdelin L, Gjerris F, Sørensen PS, Rafaelsen OJ, Alling C (1987): CSF-amine metabolites in depression, dementia and in controls. Acta Psychiatr Scand 75:619-628.
24. Goldman D, Dean M, Brown GL, et al (1992): D2 dopamine receptor genotype and cerebrospinal fluid homovanillic acid, 5-hydroxyindoleacetic acid and 3-methoxy-4-hydroxyphenolglycol in alcoholics in Finland and the United States. Acta Psychiatr Scand 86:351-357.
25. Grandy DK, Litt M, Allen L, et al (1989a): The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. Am J Hum Genet 45:778-785.
26. Grandy DK, Marchionni MA, Makam H, et al (1989b): Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc Natl Acad Sci USA 86:9762-9766.
27. Growe WM, Andreasen N (1982): Simultaneous tests of many hypotheses in exploratory research. J Nerv Ment Dis 170:3-8.
28. Hartikainen P, Soininen H, Reinikainen KJ, Sirviö J, Soikkeli R, Riekkinen PJ (1991): Neurotransmitter markers in the cerebrospinal fluid of normal subjects. Effects of aging and other confounding factors. J Neural Transm 84:103-117.
29. Hauge XY, Grandy DK, Eubanks JH, Evans GA, Civelli O, Litt M (1991): Detection and characterization of additional DNA polymorphisms in the dopamine D2 receptor gene. Genomics 10:527-530.
30. Higley JD, Thompson WW, Champoux M, et al (1993): Paternal and maternal genetic and environmental contributions to cerebrospinal fluid monoamine metabolites in rhesus monkeys (Macaca mulatta). Arch Gen Psychiatry 50:615-623.
31. Hsiao JK, Colison J, Bartko JJ, et al (1993a): Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics. Arch Gen Psychiatry 50:606-614.
32. Hsiao JK, Potter WZ, Ågren H, Owen RR, Pickar D (1993b): Clinical investigation of monoamine neurotransmitter interactions. Psychopharmacology 112:S76-S84.
33. Jönsson E, Lannfelt L, Sokoloff P, Schwartz J-C, Sedvall G (1993): Lack of association between schizophrenia and alleles in the dopamine D3 receptor gene. Acta Psychiatr Scand 87:345-349.
34. Kahn RS, Davidson M, Knott P, Stern RG, Apter S, Davis KL (1993): Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment. Arch Gen Psychiatry 50:599-605.
35. Knott P, Haroutunian V, Bierer L, et al (1989): Correlations postmortem between ventricular CSF and cortical tissue concentrations of MHPG, 5-HIAA and HVA in Alzheimer's disease. Biol Psychiatry 25:112A.
36. Kopin IJ, Gordon EK, Jimerson DC, Polinsky RJ (1983): Relation between plasma and cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylglycol. Science 219:73-75.
37. Lannfelt L, Sokoloff P, Martres M-P, et al (1992): Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr Genet 2:249-256.
38. Laurent C, Savoye C, Samolyk D, et al (1994): Homozygosity at the dopamine D3 receptor locus is not associated with schizophrenia. J Med Genet 31:260.
39. Lehmann J, Langer SZ (1983): The striatal cholinergic interneuron: Synaptic target of dopaminergic terminals. Neuroscience 10:1105-1120.
40. Lichter JB, Barr CL, Kennedy JL, Van Tol HHM, Kidd KK, Livak KJ (1993): A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum Molec Genet 2:767-773.
41. Lindström LH (1985): Low HVA and normal 5-HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: Correlations to symptomatology and family history. Psychiatry Res 14:265-273.
42. Losonczy MF, Mohs RC, Davis KL (1981): Seasonal variations of human lumbar CSF neurotransmitter metabolite concentrations. Psychiatry Res 12:79-87.
43. Macciardi F, Verga M, Kennedy JL, et al (1994): An association study between schizophrenia and the dopamine receptor genes DRD3 and DRD4 using haplotype relative risk. Hum Hered 44:328-336.
44. Mant R, Williams J, Asherson P, Parfitt E, McGuffin P, Owen MJ (1994): Relationship between homozygosity at the dopamine D3 receptor gene and schizophrenia. Am J Med Genet 54:21-26.
45. Moir ATG, Aschcraft GW, Crawford TBB, Eccleston D, Goldberg HC (1970): Cerebral metabolites in cerebrospinal fluid as a biochemical approach to the brain. Brain 93:357-368.
46. Murray AM, Ryoo HL, Gurevich E, Joyce JN (1994): Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci USA 91:11271-11275.
47. Nagatsu T, Levitt M, Udenfriend S (1964): Tyrosine hydroxylase: The initial step in norepinephrine biosynthesis. J Biol Chem 239:2910-2917.
48. Nanko S, Sasaki T, Fukuda R, et al (1993): A study of association between schizophrenia and dopamine D3 receptor gene. Hum Genet 92:336-338.
49. Nielsen DA, Goldman D, Virkkunen M, Tokola R, Rawlings R, Linnoila M (1994): Suicidality and 5-hydroxyindoleacetic acid concentration associated with a tryptophan hydroxylase polymorphism. Arch Gen Psychiatry 51:34-38.
50. Nimgaonkar VL, Zhang XR, Caldwell JG, Ganguli R, Chakravarti A (1993): Association study of schizophrenia with dopamine D3 receptor gene polymorphisms: Probable effects of family history? Am J Med Genet 48:214-217.
51. Nordin C (1989): Gradients of monoamine metabolites in relation to position of the lumbar puncture needle. Biol Psychiatry 25:513-516.
52. Nordin C, Siewers B, Bertilsson L (1982): Site of lumbar puncture influences levels of monoamine metabolites. Arch Gen Psychiatry 39:1445.
53. Nordin C, Swedin A, Zachau AC (1992): CSF 5-HIAA and atmospheric pressure. Biol Psychiatry 31:644-645.
54. Nordin C, Swedin A, Zachau A (1993): Tapping-time influences concentrations of 5-HIAA in the CSF. J Psychiatr Res 27:409-414.
55. Nordström P, Samuelsson M, Åsberg M, et al (1994): CSF 5-HIAA predicts suicide risk after attempted suicide. Suicide Life Threat Behav 24:1-9.
56. Nöthen MM, Cichon S, Propping P, et al (1993): Excess of homozygosity at the dopamine D3 receptor gene in schizophrenia not confirmed. J Med Genet 30:708.
57. Oxenstierna G, Edman G, Iselius L, Oreland L, Ross SB, Sedvall G (1986): Concentrations of monoamine metabolites in the cerebrospinal fluid of twins and unrelated individuals - A genetic study. J Psychiatr Res 20:19-29.
58. Polymeropoulos MH, Xiao H, Rath DS, Merril CR (1991): Tetranucleotide repeat polymorphism at the human tyrosine hydroxylase gene (TH). Nucl Acids Res 19:3753.
59. Post RM, Goodwill FK, Gordon E (1973): Amine metabolites in human cerebrospinal fluid: Effects of cord transection and spinal fluid block. Science 179:897-899.
60. Roy A, Adinoff B, DeJong J, Linnoila M (1991a): Cerebrospinal fluid variables among alcoholics lack seasonal variation. Acta Psychiatr Scand 84:579-582.
61. Roy A, Virkkunen M, Linnoila M (1991b): Serotonin in suicide, violence, and alcoholism. In Coccaro E, Murphy D (eds), Serotonin in Major Psychiatric Disorders. Washington, DC: American Psychiatric Association, pp 187-208.
62. Saha N, Tsoi WF, Low PS, Basair J, Tay JSH (1994): Lack of association of the dopamine D3 receptor gene polymorphism (Ba1I) in Chinese schizophrenic males. Psychiatr Genet 4:201-204.
63. Scheinin M (1985); Monoamine metabolites in human cerebrospinal fluid: Indicators of neuronal activity? Med Biol 63:1-17.
64. Sedvall G, Alfredsson G, Bjerkenstedt L, et al (1975): Selective effects of psychoactive drugs on levels of monoamine metabolites and prolactin in cerebrospinal fluid of psychiatric patients. Proceedings from Sixth International Congress of Pharmacology, Forssa, Finland. Forssa: Forssan Kirjapaino OY, pp 255-267.
65. Sedvall G, Fyrö B, Gullberg B, Nybäck H, Wiesel F-A, Wode-Helgodt B (1980): Relationships in healthy volunteers between concentrations of monoamine metabolites in cerebrospinal fluid and family history of psychiatric morbidity. Br J Psychiatry 136:366-374.
66. Shaikh S, Collier D, Kerwin RW, et al (1993): Dopamine D4 receptor subtypes and response to clozapine. Lancet 341:116.
67. Sharma RP, Javaid JI, Faull K, Davis JM, Janicak PG (1994): CSF and plasma MHPG, and the CSF MHPG index: Pretreatment levels in diagnostic groups and response to somatic treatments. Psychiatry Res 51:51-60.
68. Spitzer RL, Williams JBW, Gibbon M (1986): Structured Clinical Interview for DSM-III-R - Non Patient Version (SCID-NP). New York: Biometrics Research Department, New York State Psychiatric Institute.
69. Stanley M, Träskman-Bendz L, Dorovini-Zis K (1985): Correlations between aminergic metabolites simultaneously obtained from human CSF and brain. Life Sci 37:1279-1286.
70. Swahn C-G, Sandgärde B, Wiesel F-A, Sedvall G (1976): Simultaneous determination of the three major monoamine metabolites in brain tissue and body fluids by a mass fragmentographic method. Psychopharmacology 48:147-152.
71. Swedo SE, Kruesi MJP, Leonard HL, et al (1989): Lack of variation in pediatric lumbar cerebrospinal fluid neurotransmitter metabolite concentrations. Acta Psychiatr Scand 80: 644-649.
72. Träskman L, Åsberg M, Bertilsson L, Sjöstrand L (1981): Monoamine metabolites in CSF and suicidal behavior. Arch Gen Psychiatry 38:631-636.
73. Träskman-Bendz L (1980): Depression and suicidal behavior - A biochemical and pharmacological study. Thesis. Karolinska Institute, Stockholm.
74. Wester P, Bergström U, Eriksson A, Gezelius C, Hardy J, Winblad B (1990): Ventricular cerebrospinal fluid monoamine transmitter and metabolite concentrations reflect human brain neurochemistry in autopsy cases. J Neurochem 54:1148-1156.
75. Wiesel F-A (1975): Mass fragmentographic determination of acidic dopamine metabolites in human cerebrospinal fluid. Neurosci Lett 1:219-224.
76. Wiesel F-A, Fyrö B, Nybäck H, Sedvall G, Wode-Helgodt B (1982): Relationships in healthy volunteers between secretion of monoamine metabolites in urine, and family history of psychiatric morbidity. Biol Psychiatry 17:1403-1413.
77. Wiesel F-A, Bjerkenstedt L, Herlofsson J, et al (1984): Psychiatric morbidity within the family and steady-state levels of cerebrospinal fluid monoamine metabolites. In Usdin E, Carlsson A, Dahlström A, Engel J (eds), Cathecolamines, Part C: Neuropharmacology and Central Nervous System -Therapeutic Aspects. New York: Liss, pp 131-138.
78. Wirz-Justice A, Wehr T (1979): Seasonality in affective illness. Sci Proc Am Psychiatr Assoc 132:307 (61B).
79. Wode-Helgodt B, Sedvall G (1978): Correlations between height of subject and concentrations of monoamine metabolites in cerebrospinal fluid from psychotic men and women. Commun Psychopharmacol 2:177-183.
80. Yang L, Li T, Wiese C, et al (1993): No association between schizophrenia and homozygosity at the D3 dopamine receptor gene. Am J Med Genet 48:83-86.